Karsy Michael, Guan Jian, Cohen Adam, Colman Howard, Jensen Randy L
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT 84132, USA.
Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.
Neurosurg Clin N Am. 2016 Apr;27(2):249-60. doi: 10.1016/j.nec.2015.11.002. Epub 2016 Feb 18.
Meningiomas are benign tumors of the central nervous system, with low recurrence risk for World Health Organization (WHO) grade I lesions but a high risk for WHO grade II and III lesions. Current standard treatments include maximum safe surgical resection when indicated and radiation. Only three systemic therapies alpha-interferon, somatostatin receptor agonists, and vascular endothelial growth factor inhibitors are currently recommended by the National Comprehensive Cancer Network for treatment of recurrent meningioma. This paper aims to review medical approaches in the treatment of meningiomas.
脑膜瘤是中枢神经系统的良性肿瘤，世界卫生组织（WHO）I级病变的复发风险较低，但WHO II级和III级病变的复发风险较高。目前的标准治疗方法包括在有指征时进行最大安全限度的手术切除以及放疗。美国国立综合癌症网络目前仅推荐三种全身治疗方法——α-干扰素、生长抑素受体激动剂和血管内皮生长因子抑制剂——用于复发性脑膜瘤的治疗。本文旨在综述脑膜瘤治疗的医学方法。
